Zhitong Finance App News, Jiuzhitang (000989.SZ) announced that on November 13, 2026, the company's holding subsidiary Jiuzhitang Aesthetic (Beijing) Cell Technology Co., Ltd. (“Beijing Ameke”) and the clinical trial lead unit Guangzhou Medical University First Affiliated Hospital organized a “multi-center, randomized, double-blind, placebo-controlled phase IIb clinical trial to evaluate the efficacy and safety of human bone marrow mesenchymal stem cell (hBMMSc) injection in the treatment of autoimmune alveolar proteinosis (aPAP)”.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.